The cell-surface receptor HER2 was selected as the target antigen because it is upregulated in several carcinoma subtypes, including breast and ovarian cancer, and is bound by a well-validated nanobody, 5F7 (ref. 37). The gene discussed is CD177; the disease is carcinoma.